StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/301% above fair value
$14.72−0.49 (-3.22%)

Close on Nov 17, 2026Market cap $800.28MP/E –Yield –

Beta Bionics r&d expenses

Research and development expenses are spending on new products and technology.

Beta Bionics's R&D Expenses for the twelve months ending Sep 30, 2026 was $42.70M, up 26.1% year over year. For fiscal 2025 it was $34.79M, up 32.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$34.79M+32.9%
FY2024Dec 31, 2024$26.18M+45.9%
FY2023Dec 31, 2023$17.94M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$11.98M+46.1%
Q2 FY2026Jun 30, 2026$10.24M+15.4%
Q1 FY2026Mar 31, 2026$10.36M+36.4%
Q4 FY2025Dec 31, 2025$10.13M+10.0%
Q3 FY2025Sep 30, 2025$8.20M+59.4%
Q2 FY2025Jun 30, 2025$8.87M+39.7%
Q1 FY2025Mar 31, 2025$7.59M+38.5%
Q4 FY2024Dec 31, 2024$9.21M–
Q3 FY2024Sep 30, 2024$5.14M–
Q2 FY2024Jun 30, 2024$6.35M–
Q1 FY2024Mar 31, 2024$5.48M–

More Beta Bionics figures

See a number that looks wrong?